Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease

Abstract

Objective. To investigate the correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease (CHD). Methods. One hundred and twenty patients with CHD admitted in our hospital were selected as the research object, including 60 patients with acute coronary syndrome as the ACS group, and 60 patients with stable angina as the SA group. Another 60 patients without CHD who were examined in our hospital at the same time were included in the non-CHD group. The patients with CHD were further divided into the control group (CG) (n = 42, with routine treatment) and the study group (SG) (n = 78, with routine treatment and rosuvastatin) to measure serum RBP4, hs-CRP, and IL-27 levels and analyze the correlation between each index and rosuvastatin in the treatment of CHD. Results. After retrospective analysis, no significant difference was found among the ACS group, the SA group, and the non-CHD group ( P > 0.05). As for serum RBP4, hs-CRP, and IL-27 levels, ACS group > SA group > non-CHD group, with obvious differences among groups ( P < 0.05). After Spearman correlation analysis, a positive correlation was observed between Gensini score and serum RBP4, hs-CRP, and IL-27 levels in patients with CHD ( P < 0.05). After treatment, serum RBP4, hs-CRP, and IL-27 levels were gradually reduced. At 4 weeks after treatment, serum RBP4, hs-CRP, and IL-27 levels of the CG and the SG were decreased conspicuously, and compared with the control, each index of the SG was obviously lower ( P < 0.05). Conclusion. Serum RBP4, hs-CRP, and IL-27 play an important role in the occurrence and development of CHD, with a positive correlation to the Gensini score, which can indicate the severity of cardiovascular disease to a certain extent. Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis.

Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis

“…Studies have shown that inflammatory response actives an important part in changing coronary plaques. [40] hs-CRP is an important inflammatory factor and elevated hs-CRP can predict the increasing risk of CHD. Our meta-analysis revealed that ZXGD could decrease hs-CRP.…”

Cytokine profile in the patients with combined cardio- and ophtalmopathies

“…При сочетании ИБС с артериальной гипертензией диагностировано увеличение IL-10 до 49,7±2,8 пг/мл против 10,2±3,0 пг/ мл в группе соматических здоровых лиц зрелого возраста [6]. Сообщается также о важной роли в возникновении и развитии ИБС IL-27 [18], IL-23, IL-35 [17], IL-34 [14], но сочетание ИБС с глаукомой не рассматривается, что определяет значимость настоящего исследования.…”

“…Однако изменения цитокинов в крови изучаются, как правило, раздельно среди пациентов с ИБС и среди пациентов с глаукомой. Показано увеличение ряда цитокинов -IL-1β и IL-10 [6], IL-5, IL-6, IL-6R, TNFα, IFNγ [9], IL-25 и IL-27 [18,19] в качестве факторов риска ИБС. Сообщается также об участии интерлейкинов крови в патогенезе глаукомы [3,4].…”

Epicardial Adipose Tissue and Diabetic Cardiomyopathy

“…35,36 In addition, higher levels of RBP4 and lower levels of GLUT4 were found in EAT, which can increase the harm of cardiovascular diseases. 37 Studies have shown that 38 serum RBP4 positively correlates with the Gensini score, which can reflect the severity of coronary arteries to a certain extent. More importantly, RBP4 and NT-proBNP have the same value in predicting the prognosis of chronic heart failure.…”